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Prognostic factors of patients with acute myeloid leukemia (AML) 
allografted in first complete remission: an analysis of the EORTC-
GIMEMA AML 8A trial
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remission
The Leukemia Cooperative Groups of the EORTC and 
the GIMEMA conducted a prospective randomized 
phase III trial, in order to assess the value of autologous 
BMT (ABMT) vs a second intensive consolidation 
course (IC2), following a common intensive consoli­
dation course (IC1) for patients with AML. Patients
Intensification of induction chemotherapy regimens 
improvement of
and
care have significantly
increased the rate of complete remission (CR) in acute
with an HLA-identical sibling donor were not ran- myeloid leukemia (AML).1,3 7 Thus, 60 to
domized, but were included in an allogeneic BMT 
(alloBMT) program. This is an analysis of prognostic 
factors which influence the outcome of treatment after 
alloBMT in first complete remission (CR). The study
of adult
patients younger than 60 years of age achieve a CR after 
one to three courses of induction treatment.1 
conventional consolidation and maintenance 
the duration of CR has remained relatively
included 730 patients <46 years of age in CR, 270 hav- median remission duration ranging from 10 to 20 months
ing a histocompatible sibling donor. In 169 of these pati- in most studies and reported 5-year disease-free survival
ents alloBMT was performed in first CR. Early remit- (-DFS) rates of less than 25%.' <’8
ters (122 patients achieving CR with one course of 
treatment) had a DFS at 3 years of 67%, significantly 
longer than that of 44% for late remitters (47 patients 
achieving CR after more than one course of treatment)
in DFS ratesremission therapy has recently res 
39%.9 High doses of chemotherapy followed by autologous
s peripheral blood2 marrow tn antation or i
(P 0.006). The relapse risk for early vs late remitters
stem cell infusion is gaining support with DFS at 3 years 
ranging from 31 to 79%.10,11 However, due to potential
was 16 and 40% at 3 years (P = 0.001) and the treat- reinfusion of leukemic cells and the absence of the graft- 
ment-related mortality (TRM) at 2 years was 21 v.v 27%.
Age appeared to be a prognostic factor for TRM, WBC
versus-leukemia effect, the relapse risk remains a concern, 
ranging from 29 to 52%).111
for DFS, whereas the FAB classification was not of followed by alloBMT has
prognostic importance. Patients with poor risk cyto- to 60% of cases, if i is pei
term in 45
in first CR. i
genetic abnormalities showed a trend towards a higher The reported relapse risk ranges from 12 to 44%). 
relapse risk. Patients transplanted shortly after achiev-
i.i
role of alloBMT is to determine as the treatment
ing CR appeared to have a worse prognosis than those results are biased when comparing them with that of other 
transplanted further into remission. Overall, the num- treatment modalities. AlloBMT for AML patients in first
A -ber of courses of induction therapy needed to achieve remission is generally restricted to patients with an 
CR was the most important prognostic factor for out- identical sibling donor. Selection of patients for BMT who
come after allogeneic BMT.
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are in good condition occurs, excluding patients who have 
persistent infections or other medical complications. Bias 
also occurs because of the variation in interval between 
achieving CR and performing BMT.4 Therefore patients 
who relapse rapidly are differentially excluded. The results 
obtained by alloBMT, when performed during first CR, are 
mainly due to the activity of combined high-dose cyelopho-
sy/y.-Ji
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sphamide and supralethal total body irradiation (TBI).14 
AlloBMT may also confer an imimmologically mediated
myeloproliferative diseases or myelodysplastic disorders of 
more than 6 months duration were ineligible. Patients with
graft-versus-leukemia effect.12,15 The major reasons for fail- severe heart, renal, hepatic or neurological concomitant dis-
ure following alloBMT are toxicities related to the trans­
plant procedure itself,®4 such as graft-versus-host disease,
infections.12 Approxi-
ease were excluded. All patients were informed of the treat­
ment and the involved risks, and gave their formal consent.
interstitial pneumonia and
mately 20% of patients die from transplant-related compli­
cations within 6 months. The incidence of transplant-related 
complications increases with advancing age and most cen- Patients were registered at diagnosis and induction treat-
Methods
ters do not perform BMTs in patients who are more than 
45 years of age.12
Several factors such as 
American-British (FAB) 
abnormalities have been described as prognostic factors in
peripheral WBC, French- 
:ation and cytogenetic
ment was subsequently given. The induction regimen con­
sisted of daunorubicin (DNR): 45 mg/m2 on days 1, 2 and 
3, i.v. push injection; Ara-C: 200 mg/m2 continuous i,v. 
infusion each day from days 1 to 7.
Evaluation of response was done at 4 weeks. In cases of
AML.13,16-10 However, these factors are often not inde- partial remission a second induction cycle was administered
pendent, but interrelated and reproducibility between stud whereas resistant cases received salvage therapy which was
ies has been low due to heterogeneity of the studies. The given outside the protocol and consisted mainly of high- 
importance of these factors is therefore unclear. The objec- dose Ara-C and m-AMSA or the MEC 
tive of this analysis was to identify factors present at diag- (mitoxantrone, etoposide and Ara-C).
nosis which are of prognostic importance for the relapse Patients entering CR after one or two courses of indue
risk, treatment-related mortality (TRM) and disease-free tion therapy received a first intensive consolidation course,
survival (DFS) after allogeneic bone marrow transplan- 4 weeks after the beginning of the (last) induction course,
tation in first complete remission. The aim was to evaluate Intensive consolidation consisted of: Ara-C 500 mg/m2 by 
whether known prognostic factors for achieving CR (WBC,
FAB, age, cytogenetics) are still of prognostic value after 
alloBMT. In other words, the aim was to analyze whether 
bone marrow transplantation has any influence on factors
a 2-h i.v. infusion, every 12 h for 6 days and of amsacrine 
(AMSA) 120 mg/m2 intravenously, on days 5, 6 and 7.
CR was confirmed by blood and BM examination 3 
weeks after the end of this consolidation course. At that
which were initially of prognostic importance. The second time, where there was an HLA-A and B identical sibling 
aim was to investigate those factors related to the respon- the MLC was performed, followed eventually by an
siveness of patients to chemotherapy, for instance, the time alloBMT. This can be considered as a randomization by
between diagnosis and the assessment of CR or the number genetic chance. Patients not elected for alloBMT, with con
of courses to reach CR, and also the interval between CR 
and alloBMT. What was the outcome of those patients 
transplanted rapidly after achieving CR, without full hema­
tological and clinical recovery? The third objective was to
firmed CR were randomized for either a second intensive 
consolidation or for autologous BMT.
The conditioning regimen for alloBMT was left to the 
discretion of the clinician and consisted of cyclophospham-
explore the influence of treatment-related factors such as ide 60 mg/kg/day on 2 consecutive days and total body 
conditioning regimen and prevention of graft-versus-host irradiation, either 9-10 Gy in a single fraction or 12 Gy in
four to six fractions over 2 or 3 days, with lung blocks after 
6, 8 or 10 Gy, respectively. Alternately, in 31% of alloBMT
disease (GVHD).
The AML 8A protocol of the EORTC Leukemia Cooper­
ative Group in collaboration with GIMEMA was the first patients the conditioning regimen consisted of a combi- 
prospective study comparing alloBMT with ABMT and nation of busulfan 4 mg/kg/day on days- 6  to -3  and cyclo- 
intensive consolidation chemotherapy. More than 1000 pat- phosphamide 60 mg/kg/day on days - 2  and -1 . Prophylaxis 
ients have been prospectively registered in this study. A for GVHD following alloBMT consisted of cyclosporin A 
comparison of the three treatment options has recently alone (37%), cyclosporin A and methotrexate (50%) and
been published. 20
Patients and methods
'Sign
The AML 8A was a prospective trial conducted between 
November 1986 and April 1993 by the EORTC LCG and 
GIMEMA, involving 60 European centers.
other (2%). Eleven percent of the patients received no treat­
ment for the prevention of GVHD. T cell depletion of the 
transplant before reinfusion was performed in 24 patients 
(17%), mainly by counterflow élutriation or with Campath-
1-G.
Some centers from the GIMEMA group excluded their 
promyelocytic (M3) acute leukemia patients, and gave
AML
Statistical analysis
Entrv criteria
AML
The DFS was calculated from the date of alloBMT until 
the date of first relapse or date of death in first CR. For the 
30% calculation of the cumulative risk of relapse over time, the 
blast cells in bone marrow smears, aged between 10 and same type of analysis as for DFS was made, except for 
45 years old were included in the study. Blast crises of patients who died in first CR, who were censored at time 
chronic myeloid leukemia and leukemias arising after other of death. Treatment-related mortality (TRM) was calculated
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from the date of alloBMT until the date o f  death in first 380 did not. One hundred and ninety-nine patients with a
CR (date of relapse = censored observation). The duration eventually underwent transplan-
of survival corr 
date of death.
Actuarial curves were calculated according to the 
Kaplan-Meier technique.21 The standard error (s.e.) was
s to the time from alloBMT to the tation. Reasons for not performing alloBMT were: refusal
by patient or donor, patient lost to follow-up, toxic or early 
death, relapse before alloBMT, medical decisions and tox­
icity of treatment (Table 1).
calculated according to the Greenwood formula.22 The One hundred and seventy patients were transplanted in 
Kaplan-Meier estimate at 3 years ±  1.96 s.e. generally rep- first complete remission and 29 at another stage of the dis- 
resents the 95% confidence interval. The ease.
between curves were tested for statistical significance using 
the two-tailed Iogrank test.23 In cases of ordered variables, 
the Iogrank test for linear trend was used. The stratified
Description o f patients allografted in first CR
Iogrank test has been used to test for relative prognostic The median age of patients allografted in first complete
importance of one variable regarding another one (eg white remission was 32 years (range: 13-45, mean 31.25), 54%
blood cell count according to the number of courses of were male and 46% female. The distribution of FAB types
induction therapy to achieve a complete remission). The was: M l, 14%; M2, 42%; M3, 5%; M4, 20%; M5, 15%;
relative risk (RR) of having an event per time unit in one M6, 2%; unknown, 2%. The median white blood cell count
category of patients vw another one (‘baseline’ category) at diagnosis was 13.7 x 1071 (range: 0.40 to 360.0 X 1071).
was estimated using the O/E ratio technique;24 the 95% The mean time from diagnosis to complete remission was 
confidence interval of the RR was computed for two categ­
orical variables using the odds-ratio technique.24
Results
42 days (range: 20 to 137 days; median: 32 days) and the 
mean time from CR to allogeneic bone marrow transplan­
tation was 116 days (range, 4 to 338 days; median, 106
Patient characteristics
Nine hundred and fifty-two newly diagnosed, untreated pat­
ients, less than 46 years of age, were registered in the study. 
The median age was 32 years (range: 11 to 45), 51% of 
the patients were male, 49% female. The distribution of 
FAB types was as follows: M l, 16%; M2, 33%; M3, 6%; 
M4, 20%; M5, 19%; M6, 4%; M7, 1%; unknown, 1%. The 
median white blood cell count was 16.6 x 1071 (range: 0.20 
to 376.0 x 1071). Out of 952 patients registered 31 patients 
were either ineligible or inevaluable, because of inadequate 
diagnosis or missing data.
R ei 11 i ss i on- i n d u c ti o n th e rap);
All 921 eligible and evaluable patients, less than 46 years 
old, were treated according to the protocol with rémission- 
induction therapy. Five hundred and two patients achieved
remission (CR) after one course (55%). In 
addition, 110 patients achieved CR after a second course 
of rémission-induction therapy (12%) and 118 after one or 
two courses of salvage therapy. Altogether, 730 out of 921 
patients achieved complete remission (79%).
Ninety-three percent of patients achieving CR after one 
or two induction courses received a first intensive consoli­
dation course. This information is not available for the pati­
ents who were given salvage therapy. The overall DFS at 
3 years for the 730 patients achieving CR was 37% (s.e. 
= 1.9%).
Donor availability and allogeneic bone marrow 
trans
Family HLA-typing was reported in 650 patients (89%) of 
the 730 patients included in the analysis. Two hundred and 
seventy patients had an HLA-identical sibling donor and
Overall results
The date of alloBMT was missing for one patient, so this 
patient was excluded from the analysis. Median follow-up 
from alloBMT for the 169 patients transplanted in first CR
was 3 years and 5 months (range, 3 months). The dis
ease-free survival at 3 years for these patients was 60% 
(s.e. =
treatment-related mortality at 2 years was 22%- (s.e.
3.9%) and the relapse risk 23% (s.e. = 3.7%). The
)
(Figure 1). In fact 35 patients have died in first CR, all but 
five within 6 months of transplantation. The cause of death
for patients is: interstitial (seven
patients), other infections (nine patients), hemorrhage (three 
patients), GVHD (nine patients), liver veno-ooclusive dis­
ease (one patient), cardiovascular disease
toxicides (three ind causes (two
Number o f courses and time to achieve first complete
rémission
Patients were divided into early and late remitters. Karly 
remitters were the 122 patients who achieved CR after one
Tabic 1 Reasons for not performing alloBMT in patients will) a liisto-
eompatible sibling donor
■ka
Reason
>1 IÉ ■ •" “> -.A »i.-.
Refusal
No.
** “i. I • • — — • — • — . • jt w, • • »— - , >. — i-,,, i . r. ... * • r * i • ' ,<•
ll>
Lost to follow-up 
Toxic/early death 
Early relapse 
Medical decision 
Toxicity 
Unknown
Total
7
15
f t
17
5
71
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of late responders in comparison to those transplanted more 
than 8 weeks after achieving CR (26% late responders).
60%
23%
Age
The DFS at 3 years after BMT was 70% for patients 
younger than 26 years. This was longer than the DFS of 
59% of patients between 26 and 35 years of age or 55% 
of patients older than 35 years of age, but the differences 
were not significant (Table 2). The relapse risks of the three 
different age groups were also not significantly 
Patients between 36 and 45 years of age had a higher TRM 
at 3 years than younger patients (36-45 years, 33%; 26-35
Figure 1 Overall results from BMT. n = number of patients; o  = years, 18%; «s25 years, 13%; P = 0.02). For the older pati- 
observed number of ‘events’; Rei R = cumulative relapse risk; TRM = ent group the risk of dying per time-unit in first CR is 2.87
H
0 1 2 3 4
Years
5 6 7 8
treatment-related mortality (cumulative probability of dying in first CR); 
disease-free survival = probability of remaining alive in first CR.
times higher than that of patients less than 26 years of age.
course of rémission-induction treatment. Late remitters 
were the remaining 47 patients who needed more courses 
of remission-induction or salvage treatment to achieve CR. 
At 3 years there were still 49 early remitters and 10 late 
remitters at risk. Table 2 shows the results for patients, 
according to the number of courses to achieve CR (early 
and late remitters), as well as according to the time taken 
to achieve CR (< 5  weeks, 5-9 weeks, 5=10 weeks). Early 
remitters had a significantly longer DFS (Figure 2) (RR, 
2.2; 95% confidence interval 1.26-3.87) and a significantly 
lower relapse risk (Figure 3) compared to late remitters. In 
fact, the relative risk for the relapse risk for late remitters 
is 3.97, which means that the chance of them having a 
relapse per time-unit is 3.97 times higher than that of early 
remitters (95% confidence interval 1.73-9.13). However, 
the TRM at 2 years was esvsentially the same for both 
groups of patients (RR, 1.35; 95% confidence interval 0.63- 
2.89). Similarly, patients who achieved complete remission 
within 5 weeks had a significantly longer DFS and signifi­
cantly lower relapse risk than patients who needed more 
than 5 and more than 10 weeks (DFS at 3 years: 66, 57 
and 39% respectively, P = 0.02 for linear trend; relapse 
risk at 3 years: 83, 74 and 59 respectively, P = 0.01 for 
linear tr
interval between CR and alloBMT
Patients allografted quickly (within 8 weeks) after achiev­
ing CR had a shorter DFS at 3 years post-transplant, com­
pared to patients allografted after 8, 16 and 24 weeks of 
complete remission, but this difference was not significant 
(Table 2). The relapse risk observed at 3 years and TRM 2 
years post-BMT were also not significantly different. When 
comparing patients transplanted within 8 weeks of achiev­
ing complete remission to all patients transplanted after 8 
weeks of CR, the differences in DFS and TRM do reach a
Cytogenetic data
Patients were categorized according to cytogenetic abnor­
malities.16 Good prognostic cytogenetic abnormalities were 
considered to be t(8;21), t(15;17) and in v i6. Patients with 
normal metaphases and -Y  were considered to have an 
intermediate prognosis. Poor prognostic cytogenetic abnor­
malities were trisomy 8, 5q-, monosomy 5 and 7 and all 
other cytogenetic abnormalities, including complex abnor­
malities. Analysis of cytogenetics at diagnosis was perfor­
med in 61 patients allografted in first CR. Among these 
patients, 11 relapses have been reported and 17 patients 
died in first CR. There was a trend to a higher relapse risk 
at 3 years for patients with poor prognostic cytogenetic 
abnormalities, compared to good and intermediate groups 
(poor, 43%; intermediate, 21%; and good, 8%), but due to 
the low number of relapses observed this difference only 
reached borderline significance (P = 0.06). The TRM at 2 
years was similar in the three groups (good, 26%; inter­
mediate, 32%; poor, 33% at 3 years, P = 0.98) (Table 2).
WBC
The WBC (x l0 9/l) at diagnosis appeared to be not only of 
prognostic value (see Table 2) for the duration of remission 
(P = 0.07), but also for the TRM (P = 0.03). There was a 
strong relationship between the WBC and DFS (P = 0.005), 
ie the higher the WBC, the worse the prognosis at 3 years 
(<10, 74%; 10-49, 54%; ^=50, 47%). In a bivariate analy­
sis, the prognostic importance of the WBC was 
according to the number of courses of remission-induction 
treatment needed to achieve CR. The WBC remained an 
independent prognostic factor for TRM (P = 0.03) and DFS
CP 0.01).
FAB classification
significant level (DFS, P = 0.003, TRM, P = 0.005). The The FAB classification, when evaluating each subgroup
DFS (31%) was shorter in those patients who were allog- separately, had no significant predictive value for outcome
rafted within 8 weeks after achieving CR. Among the 13 post-BMT in this analysis (Table 2). When comparing FAB
patients in this group, three relapses were reported and six M4 and M5 vs the other FAB subgroups no significant dil-
deaths in CR. The group of patients transplanted within 8 ference was found in terms of DFS, TRM or relapse risk,
weeks of achieving CR included a higher percentage (46%) Thirteen events occurred among the 60 patients with M4
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Table 2 Prognostic factor analysis for patients who have been allografted in first CR
Variable n Relapse risk
O Est (%) s.e. (%) P value
CR achieved
1 induction 122 15 16 3.8
>1 induction 47 15 40 8.1
Time to CR (weeks):
0 -4 100 13 17 4.4
5*"9 49 10 26 7.2
s&H) 20 7 41 11.9
Interval CR and BMT (weeks):
0.6-7 13 3 42 18.6
8-15 81 15 23 5.2
16-23 55 9 21 6.3
^ 2 4 20 3 20 10.3
Age (years):
25 43 7 19 6.4
26-35 67 15 28 6.2
36-45 59 8 19 6.1
Cytogenetic group:
Good 16 1 8 7.4
Intermediate 26 4 21 9.7
Poor 19 6 43 13.7
WBC (X1071):
0 -9 68 9 16 5.0
10-49 67 13 25 6.1oA\ 34 8 33 9.6
FAB:
M l
M2
M3
M4
M5
M6
Total
0.001
0.01
0.22
0.87
0.06
0.07
O
24
11
TKM ' 1 a
• «V,. " uv  ^iV ■*» | ‘ i » » i^ Tf i —«iv*'. ” —a r. —.. I* > • 4 * - *
Esl (%) s.e. (%) P value O Est (%) s.e. (%) P value
I
11 
A *  /
3.8
7.4
* VI .  ■ .vu !•* * w ■ *. 1*. «  ' ' - • ■ t > • 1 1 •  !■ '■ w 1 hi '  ml‘J  j. n ■■ u  ^  >« <1 '  ‘ ■ rr A «  r\+ »M* u.j>'
0.44
39
26
67
*44*
4.4
7.4
24 3 15 8.1 5 22 8.9 8 66 9.8
70 14 26 6.0 14 5.2 28 58 6.1
9 0 0 0.52“ 1 11 10.5 0.83" 1 89 10.5
34 6 28 10.1 9 26 7.6 15 53 C) 0
26 7 31 9.7 4 19 8.8 11 56 10.0
3 0 0 ---------- « 1 33 27 ■?+ +  9  *  4m r 1 67 ~>i i  Am t 4  ■* * *
169 30 23 3.7 35 22 3.4 65 60 3.9
0.006
19 20 4.2 IT « 1 66 4.9
11 23 6.0 0.38 21 57 7.1 0.02
5 33 13.1 12 39 11.1
6 47 14.1 9 31 12.8
16 22 4.9 0.15 31 61 5.6 0.06
8 16 5.2 17 67 6.7
5 25 9.7 8 60 11.0
5 13 5.7 12 70 7.2
12 18 4.8 0.02 27 59 6.1 0 .1 1
18 33 6.4 26 55 6.6
4 26 11.0 5 69 11.6
8 32 9.5 0.98 12 53 9.9 0.22
5 33 12.5 11 38 11.7
8 13 4.2 17 74 5.6
17 27 5.8 0.03 30 54 6.2 0.005
9 30 8.6 17 47 8.9
0.66“
N = total number of patients; 0  = observed number of 'events'; Est = actuarial estimation at 3 years; s.e. = standard error of the estimate; P-value = 
given by the logrank test (for linear trend, in case of ordered variables); DFS = disease-free survival (probability to remain alive and disease-lree); TRM 
= treatment-related mortality (the estimate and standard error are taken at 2 years post-BMT as all deaths in CR occur during the first 2 years. The 
estimate and standard error will not change after this time and therefore the timepoint at 2 years is more accurate)
“The P value for FAB classification is given, but as there are so many subgroups being compared, the chance of the P value being significant is 
extremely small
100
_Q
CD
-Q
O
Cl
80 -
~  60 +
40
20
0
67%
n O
122 39 1 ind.
47 26 >1 ind. 
Logrank P= 0.006
44%
+ +
1 2 3 4
Years
5 6
+
7 8
Figure 2 DFS from BMT by number of courses to reach CR. n = number 
of patients; O = observed number of ‘events’ (ie relapses or deaths in first 
CR); disease-free survival = probability of remaining alive in first CR; 
I ind = 1 induction course needed to reach CR; >1  ind -  > 1  induction 
course needed to reach CR.
Years
Figure 3 Cumulative relapse risk from 
reach CR, n =
BMT by number of courses to
1 ind
 number of patients; O =
1 induction course needed to reach CR; >  1 ind
ir of r
> i  i
* « »
course needed to reach CR.
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or M5 sub-types and 21 events among the 109 patients with transplantation following CR in the treatment of AML. The
other FAB sub-types.
Treatment-related factors
Severa] factors which were treatment-related were investi-
patients registered at diagnosis represented a standard popu­
lation of patients with AML. The proportion of patients 
who entered first CR was comparable with results of large 
chemotherapy trials.4,25 In this analysis we assessed prog­
nostic factors of patients allografted in CR1 within the
gated for exploratory purposes. These factors were not stan- framework of the AML 8 A study. An allograft in first CR
dardized in the protocol and were left to the discretion of was performed in only 170 (63%) o f  the 270 patients with
the clinician. The results given were descriptive and no a histocompatible sibling. Twenty-nine patients were allog-
conclusions can be drawn from them; they call for confir- rafted at a later stage of the disease. This means that 74%
mation by randomized trials.
' regimen
Patients received cyclophosphamide either in combination
of patients with an HLA-identical sibling donor actually 
received alloBMT. The remaining patients who did not 
receive an alloBMT had either a poor prognosis, eg toxic or 
early death, early relapse (18%) or refused treatment (8%).
Out of 170 patients who were transplanted in first com-
with total body irradiation (TBI) or busulfan. The TBI plete remission the data were available for 169 patients. At 
could be given as a single fraction or fractionated over 2 the time of the analysis, I June 1995, the median folio w-
or 3 days. Fifty-six patients received the regimen containing up from alloBMT was 3 years and 5 months (range: 3-89
busulfan and 105 were given TBI. Twenty patients received months). The DFS of these 169 patients was 60% at 3 years
TBI in one fraction, 45 received TBI in two or three frac- after BMT. This is comparable to the results observed in
tions and 40 patients received TBI in more than three frac- other studies.26 The DFS appeared significantly longer for
tions. The remaining eight patients received a different con- patients who entered CR after one course of chemotherapy
ditioning regimen using several types of chemotherapy. The than for patients who needed more than one course. The
relapse risk at 3 years ranged from 32% for TBI given in relapse risk was significantly higher for these slow remit-
a single fraction to 12% for TBI in more than three frac- ters, but the TRM was virtually identical for both groups
tions and was 26% for patients receiving busulfan. The of patients. One could expect that patients who required
TRM at 2 years varied from 40% for TBI given in a single more chemotherapy to reach CR would respond more
fraction to 18% for TBI given in two or three fractions and poorly to the intensive conditioning regimen for transplan-
was 15% for patients receiving busulfan. The DFS at 3 
years was 41% for TBI given in a single fraction, 63%
tation, resulting in a higher TRM. This did not appear to 
be the case. The lower DFS was due to the higher relapse
when given in two or three fractions, 70% for TBI given risk. The actual time taken to achieve CR corresponded
in more than three fractions and was 63% for the patients 
receiving busulfan.
Prevention o f GVHD
Nineteen patients received no form of treatment for the pre­
vention of GVHD, 62 patients received cyclosporin A alone 
and 85 patients received a combination of cyclosporin A 
and methotrexate. The remaining three patients received 
other treatments for the prevention of GVHD. The relapse
to the number of courses of remission-induction treatment 
needed to achieve CR. For this reason the majority of pati­
ents who achieved CR within 5 weeks appeared to have a 
longer disease-free survival than the patients who achieved 
CR more than 5 weeks after starting chemotherapy. The 
higher relapse risk in the latter group of patients was 
responsible for this difference. Forman et al2(' evaluated 
only 69 patients who were allografted in first complete 
remission. They concluded that length of remission-induc­
tion therapy had no significant influence on the survival of
risk at 3 years ranged from 17% for the combination of the patient post-transplant. In most other analyses the length
cyclosporin A and methotrexate to 28% for cyclosporin A of remission-induction therapy was not taken into
alone. The TRM at 2 years varied from 16 to 29% and the account.27,28 Patients transplanted shortly after achieving
DFS at 3 years from 52 to 69%.
T cell depletion
Twenty-eight of the allografts were treated with T cell 
depletion. The relapse risk at 3 years was 37% for these 
allografts compared to 20% for non-T cell depleted allog­
rafts. The TRM at 2 years was 30 and 21% respectively, 
the DFS at 3 years 44 and 64% respectively.
Discussion
CR (< 8  weeks) appeared to have a worse prognosis than 
those patients transplanted further into remission, mainly 
due to a higher risk of relapse and a higher transplant- 
related mortality. This could be due to the fact that these 
patients might have relapsed before the transplant, had they 
waited longer for the allograft. Patients transplanted within 
8 weeks also needed more intensive chemotherapy to achi­
eve CR (46% late responders). These patients did not have 
the opportunity to recover completely before the allograft, 
resulting in a higher death rate in first CR. The relapse risk 
and the transplant-related mortality did not decrease further 
when the transplant was performed more than 8 weeks after 
achieving CR. This suggests that at least in this study a
The AML 8A study of the Leukemia Cooperative Groups further delay of the allograft beyond 8 weeks after entering
of the EORTC and GIMEMA was undertaken to assess CR did not select out a better prognostic group of patients.
role of intensive post-consolidation It is still unclear when the bone marrow transplant should 
chemotherapy, allogeneic and autologous bone marrow take place. Randomized trials may answer this question.
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The MRC, in their AML 12 trial is currently randomizing explain the fact that no 
patients into four treatment procedures: four or five courses between the remaining FAB subtypes.
erence in DFS was found
of chemotherapy or three or four courses of chemotherapy 
followed by allogeneic or autologous BMT.
Treatment-related factors such as conditioning regimen
might the survival parameters post-BMT.
The potentially higher antileukemic activity of allogeneic Ringdén et cilM) randomized 167 patients with leukemia,
BMT is counterbalanced by a higher incidence of treat- receiving marrow transplants from HLA-identical donors,
ment-related toxicities, such as severe GVHD, interstitial between cyclophosphamide with either busulfan or total
pneumonitis, infectious complications and veno-occlusive body irradiation (TBI) as conditioning regimen. They found
liver disease. This analysis showed that treatment- a higher treatment-related mortality in patients
related mortality at 2 years was 20% overall. Patients under advanced disease treated with busulfan, but no difference
the age of 25 years had a TRM of 13% and patients below concerning the relapse risk post-BMT. Other investigators
the age of 35 years had a TRM of 18% which compared have reported retrospective evaluations on single i\v frae-
favorably with the TRM of 33% in patients 36 to 45 years tionated TBI,|(>,2<’ but no significant differences in treatment
old. This indicates that the alloBMT may be deferred to a outcome were detected. In this analysis, as in the overall
later time, after a relapse, in patients older than 35 years analysis of the AML 8A study,20 no significant differences 
of age who have AML with relatively good prognostic fea­
tures such as CR after one remission-induction course and
various X i mf%e
However, such treatments were left to the discretion of the 
favorable cytogenetic features. When the results according local investigators, which means that such analyses are sub- 
to number of courses to reach CR are stratified by age, ject to bias, and one should not draw any conclusions
early remitters in each age group still have a high TRM 
and low relapse risk compared to late remitters. This means
from them.
Chao et aP 1 randomized 150 patients with hematological
that when transplanting early remitters, more should be malignancies being allografted with genotypically his to-
done to decrease the treatment-related mortality. In several compatible bone marrow between treatment with either a
prospective randomized trials, such as MRC 12 at least combination of cyclosporine, methotrexate and prednisone
three courses are given prior to the alloBMT. The data from or cyclosporine with prednisone alone. They found the
this analysis suggest that one intensive consolidation course combination including methotrexate to be more effective in
is sufficient to reduce relapse after alloBMT to 13% if CR the prevention of acute GVHD of grades II to IV, than the
is reached after one remission-induction course. More con- combination of cyclosporine and prednisone. In the overall
solidation courses are not likely to increase DFS after analysis of the AML 8A study an almost significant differ-
alloBMT. When transplanting late remitters, treatment ence in terms of DFS was found in favor of the combination
should be intensified in order to decrease the relapse risk cyclosporine and methotrexate uv cyclosporine alone, but
post-BMT. Results from several transplant teams28,29 do here no prednisone was given. In this analysis no significant
•enees in the treatment for the prevention of GVHDsuggest that age of the patient has a significant influence 
on the prognosis, but this finding is not consistent, probably 
depending on the size of the study group, selection of the discretion of the local investigator, so no conclusions can
were to
patients or the intensity of the chemotherapy prior to the 
allograft.26,27
be drawn from them.
In our series, a relative low number of relapses has been
Cytogenetic results according to the Keating criteria observed: 30 in total. For this reason a limited number of
seem to show a correlation with the relapse risk (8% at 3 factors have been considered in this analysis, in order to
years for the good prognostic group and 43% for the poor maintain the false-positive error at an acceptable level. On
prognostic group), but too few patients have been kary­
otyped in this study and therefore, probably due to low
the other hand, a low number of events implies that only 
very important prognostic factors may be detected, as the
cytogenetics). Confidence intervals were also quite large
due to the low number of events, but series may
statistical power, the observed trend was of borderline sig- statistical power is only sufficiently high for such factors 
nificance. to yield significant or almost significant results (eg WBC,
Our results confirm that the white blood cell count at 
diagnosis is a prognostic factor for disease-free survival, as 
described by Bostrom et al,21 who evaluated 39 patients 
with AML who were allografted in first complete 
remission. In our analysis, a high WBC at diagnosis was a 
poor prognostic factor for patients with AML allografted other series, where the treatment modalities (GVHD pre­
in first CR. This was also seen in the overall analysis of 
the AML 8A study.20
The uncertainty of results may be 
of ‘treatment-related factors',
which may influence the generalizability of our results to
vention etc) were different, or had been used differently. 
Our results came from transplantation teams (participating 
In contrast to data of the European Bone Marrow Trans- in the AML 8A study) of the EORTC LCG and GIMEMA, 
plantation Registry13 and also of Bostrom et al,21 our results which may be a representative sample of transplant centers
showed no increase in relapse risk for patients with FAB 
M4 or M5. Nor was there any significant difference in dis- 
ease-free survival, when comparing all FAB 
However, only nine patients in our analysis had FAB sub- TBI v.y no TBI, the number of fractions in which to deliver 
type M3, as these patients were usually treated with all- TBI and T cell depletion or not.
in Europe. There is definitely a strong need to implement 
the methods of randomized trials in the field of BMT, in 
order to evaluate properly important questions including
trans retinole acid (ATRA) and chemotherapy protocols. AlloBMT is a treatment where only a minority of pati-
FAB subtype M3 is prognostically favorable. This might ents may benefit. In this series 30% of the patients had an
1000
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HLA-identical sibling donor. Sixty percent of these patients sita Federico II (B Rotoli), and Ospedale Cardarelli (R
were actually allografted. This means that only 18% of pati- Cimino); Nuoro, S Francesco (A Gabbas);
ents were allografted and 11% of patients are long-term Palermo, Ospedale Cervello (F Caronia), and Università di 
disease-free survivors after alloBMT. Palermo (A Cajozzo); Pavia, Policlinico S Matteo (C
The aim of this analysis was to identify factors, present Bernasconi); Perugia, Università Clinica Medica (F
at diagnosis or therapy-related, which are of prognostic Grignani), and Università Istituto di Ematologia (M
importance after allogeneic bone marrow transplantation in Martelli); Pesaro, Ospedale S Salvatore (G Lucarelli); Pes-
patients, less than 46 years of age, with newly diagnosed cara, Ospedale Civile (G Torlontano); Potenza, Ospedale S
acute myeloid leukemia. The number of courses of Carlo (F Ricciuti); Reggio Calabria, Ospedale Riuniti (F
remission-induction treatment to achieve CR and the time Nobile); Roma, Il Università Tor Vergata (G Papa*, S
taken to reach CR have a significant influence on the dis- Amadori), I Università La Sapienza (F Mandelli, W Arcese,
ease-free survival of the patient post-alloBMT. The rela- and G Meloni), Università Cattolica del Sacro Cuore (B
tively high relapse risk in patients who needed more time Bizzi), and Ospedale S Camillo (A De Laurenzi); San Giov-
and chemotherapy courses to achieve CR warrants the use anni Rotondo, Ospedale Casa Sollievo della Sofferenza (M
of a more intensified conditioning regimen prior to the allo- Carotenuto); and Torino, Ospedale Maggiore S Giovanni
geneic BMT. This may also apply for those patients who Battista (L Resegotti), and Università di Torino (A Pileri).
Cytology committee: M Cadiou, M Bernier, G Den Otto- 
Iander, U Jehn, W Sizoo, GL Castoldi, S Fenu and V Liso.
Cytogenetic committee: A Hagemeijer, G Alimena, A
have poor prognostic cytogenetic abnormalities. Age was 
found to be a prognostic factor for treatment-related mor­
tality. Only analysis of prospectively registered patients can 
evaluate treatment modalities such as allogeneic bone mar­
row transplantation. Prospective randomized trials are Bernheim and A. Zaccaria.
extremely useful for this approach.
*Deceased.
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